Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Delgocitinib 20 mg/g cream for the treatment of lichen planopilaris: A case report.
Journal: JAAD case reports
Published: August 28, 2026
Severe psoriasis relapse following tralokinumab therapy for atopic dermatitis.
Journal: JAAD case reports
Published: July 10, 2026
Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.
Journal: Dermatology and therapy
Published: March 19, 2026
Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis.
Journal: The Journal of dermatological treatment
Published: March 11, 2026
Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis.
Journal: Dermatology and therapy
Published: March 03, 2026
Prurigo Nodularis paTient Reported burdEn of sicKness in Europe (PN TREK Europe): a cross-sectional survey of patient-reported burden of disease in patients with PN from four countries in Europe.
Journal: The Journal of dermatological treatment
Published: February 17, 2026
The evolving understanding of prurigo nodularis.
Journal: Clinical and experimental dermatology
Published: February 02, 2026
Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials.
Journal: Dermatology and therapy
Published: October 29, 2025
Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies.
Journal: Dermatology and therapy
Published: October 22, 2025
Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: October 18, 2025
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.
Journal: Dermatology and therapy
Published: August 26, 2025
Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study.
Journal: The British journal of dermatology
Published: July 21, 2025
Last Updated: 09/26/2026